Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and...
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.24 | 27.5862068966 | 0.87 | 1.35 | 0.82 | 2410777 | 1.22419856 | CS |
4 | 0.2199 | 24.7050893158 | 0.8901 | 1.35 | 0.8 | 1016400 | 1.10592993 | CS |
12 | 0.43 | 63.2352941176 | 0.68 | 1.35 | 0.6354 | 656592 | 0.95781437 | CS |
26 | 0.13 | 13.2653061224 | 0.98 | 1.35 | 0.6354 | 715493 | 0.91980269 | CS |
52 | -1.14 | -50.6666666667 | 2.25 | 3.1399 | 0.6354 | 522936 | 1.18411817 | CS |
156 | -10.56 | -90.4884318766 | 11.67 | 12.73 | 0.6354 | 265232 | 2.41841824 | CS |
260 | -40.91 | -97.3584007615 | 42.02 | 63.62 | 0.6354 | 242001 | 6.23538325 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales